A study suggesting that nirmatrelvir/ritonavir and molnupiravir don’t prevent severe COVID-19 outcomes or long COVID is also being called into question.
Evidence growing for COVID antivirals to cut poor outcomes, long COVID, experts say
Published in COVID-19
More from COVID-19More posts in COVID-19 »
- COVID-adapted stewardship intervention linked to reduced antibiotic use, resistance in Chicago hospital
- Common diabetes drug linked to lower rate of long COVID
- Machine-learning monoclonal antibody allocation in pandemic could cut hospital cases by a third
- COVID-infected psychiatric hospital roommates pose high risk of infection, especially in elderly